•  
  •  
  •  
  •  

2025-10-19 23:26:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • RPP Infra Projects Ltd wins new orders worth Rs. 125.92 Crores
  • Atishay Ltd receives order worth Rs. 1.97 crore
  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS

Keywords Selected:  AlembicPharmaceuticals

Stock Report

  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for facility at Panelav
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP
  • Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg
  • Alembic Pharmaceuticals Ltd recommends dividend of Rs. 11
  • Alembic Pharmaceuticals Ltd posts consolidated net profit of Rs. 156.63 crores in Q4 FY2025
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
  • Alembic Pharmaceuticals Ltd commissions new facility at Pithampur
  • Alembic Pharmaceuticals receives USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Pantoprazole Sodium for Injection, 40 mg/vial - Single-Dose Vial
  • Alembic Pharmaceuticals Ltd successfully completes USFDA inspection for API-III facility
  • USFDA inspection at Alembic Pharma's Bioequivalence Facility
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
  • Alembic Pharmaceuticals Limited passes ANVISA, Brazil GMP audit for its API-II Facility at Panelav
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Alembic Pharmaceuticals Ltd Q2 FY25 consolidated net profit at Rs. 153.41 crores
  • Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg
  • Alembic Pharmaceuticals Ltd's Oncology facility successfully completes USFDA inspection

Latest Post

  • RPP Infra Projects Ltd wins new orders worth Rs. 125.92 Crores
  • Atishay Ltd receives order worth Rs. 1.97 crore
  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024